DOACs: life-changing technologies

DOACs: life-changing technologies

VIII Eurasian Congress of Cardiology. Overview of symposiums. DOACs: life-changing technologies. Systemic Hypertension

Bibliographic Details
Main Authors:	E. P. Panchenko, R. M. Shakhnovich, F/ T. Ageev, A. L. Komarov
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2020-09-01
Series:	Системные гипертензии
Online Access:	https://syst-hypertension.ru/2075-082X/article/viewFile/42263/pdf

Similar Items

Influence of DOACS and DOAC-REMOVE® on coagulation assays during thrombophilia testing in DOAC-treated patients
by: Kovač Mirjana, et al.
Published: (2022-01-01)

DOAC in COVID-19: Yes or No?
by: Roger E. Schutgens
Published: (2021-01-01)

Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests
by: Julien Favresse, et al.
Published: (2018-04-01)

Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
by: Michael Hardy, et al.
Published: (2022-03-01)

Adverse Events of DOACs in Children
by: Alessandra Bosch, et al.
Published: (2022-07-01)

The importance of dosing frequency on the safety of DOACs
by: Christian T. Ruff
Published: (2022-11-01)

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
by: Claire Dunois
Published: (2021-04-01)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
by: Heike Schwarb, et al.
Published: (2016-03-01)

Scavenging effect of DOAC-Stop on zifaxaban in vitro and in vivo
by: ZHANG Sipei, et al.
Published: (2021-07-01)

Optimization of DOAC management services in a centralized anticoagulation clinic
by: Katelyn W. Sylvester, et al.
Published: (2022-03-01)

Direct oral anticoagulants (DOACs): From the laboratory point of view
by: Margetić Sandra, et al.
Published: (2022-12-01)

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
by: Tagore Sunkara, et al.
Published: (2016-12-01)

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
by: Tagore Sunkara, et al.
Published: (2016-01-01)

CLINICAL ANALYSIS OF A PATIENT WITH ANTIPHOSPHOLIPID SYNDROME AND SUB-MASSIVE PULMONARY EMBOLISM
by: E. N. Krivosheeva, et al.
Published: (2018-05-01)

DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives
by: Tom Langenaeken, et al.
Published: (2023-07-01)

Direct Oral Anticoagulants (DOAC): Are We Ready for a Pharmacogenetic Approach?
by: Raffaele Palmirotta
Published: (2021-12-01)

Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine
by: Job Harenberg MD, et al.
Published: (2021-03-01)

Using direct anticoagulants (DOACs) in cancer and other high-risk populations
by: Cristina Vârlan, et al.
Published: (2016-12-01)

Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors
by: Vineet Kumar, et al.
Published: (2024-02-01)

Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs)
by: Vasilios Perifanis, et al.
Published: (2021-12-01)

Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing
by: Paula Savola, et al.
Published: (2022-10-01)

Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019)
by: Joy, M, et al.
Published: (2022)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
by: Steven Andrew Baker, et al.
Published: (2021-02-01)

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
by: Nicola Ferri, et al.
Published: (2022-05-01)

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran
by: Leung TS, et al.
Published: (2015-07-01)

Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing
by: Souad Moudallel, et al.
Published: (2018-10-01)

Direct Oral Anticoagulant (DOAC) to Warfarin Transitions in a Pharmacist-led Anticoagulation Clinic
by: Ashley G. Woodhouse, et al.
Published: (2019-03-01)

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
by: Maureane Hoffman, et al.
Published: (2018-12-01)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
by: L. Slavik, et al.
Published: (2019-09-01)

The Effect of Direct Oral Anticoagulant Therapy (DOACs) on oral surgical procedures: a systematic review
by: Ghassan Darwish
Published: (2023-10-01)

Could DOAC Be a Better Choice Than Warfarin in Low Compliance Patients with Fontan Procedure?
by: Jisoo Park, et al.
Published: (2021-05-01)

Plasma Drug Values of DOACs in Patients Presenting with Gastrointestinal Bleeding: A Prospective Observational Study
by: Dorotea Bozic, et al.
Published: (2023-08-01)

Management of Traumatic Brain Injury in Patients with DOAC Therapy–Are the “New” Oral Anticoagulants Really Safer?
by: Anna Antoni, et al.
Published: (2022-10-01)

No Association between Gastrointestinal Rebleeding and DOAC Therapy Resumption: A Systematic Review and Meta-Analysis
by: Dániel Pálinkás, et al.
Published: (2023-02-01)

Personalized bleeding risk assessment for atrial fibrillation patients on direct oral anticoagulants: the DOAC score
by: Paolo Prandoni
Published: (2023-10-01)

Direct oral anticoagulant (DOAC) monitoring within primary care: a quality improvement project
by: Isobel Joy McFadzean, et al.
Published: (2023-06-01)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
by: Rachel Ryu PharmD, BCPS
Published: (2022-12-01)

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
by: Yalin Cao, et al.
Published: (2022-06-01)

DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions
by: Rachel Ryu PharmD, BCPS, et al.
Published: (2022-05-01)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
by: Viktor Taune, et al.
Published: (2022-07-01)